Regeneron Pharmaceuticals, Inc. (REGN) Company Bio
Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.
REGN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Regeneron Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 47th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for REGN, they are:
The company's debt burden, as measured by earnings divided by interest payments, is 108.12; that's higher than 95.81% of US stocks in the Healthcare sector that have positive free cash flow.
The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than just 10.83% of the free cash flow producing stocks we're observing.
REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 47.6% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Regeneron Pharmaceuticals Inc? See HRC, EBS, HBIO, DXCM, and AMED.
Luckily, there are over 300 coronavirus treatment candidates currently in various stages of preclinical and clinical studies. If successful antibody therapeutics could be developed to treat and prevent SARS-CoV-2 infections, they could be game-changers in the fight against the disease that's caused worldwide economic shutdowns and killed almost 200,000 people in the U.S. alone. GlaxoSmithKline (NYSE: GSK) and Regeneron (NASDAQ: REGN) are two companies leading the way in developing prospective antibody treatments for COVID-19.
Regeneron Pharmaceuticals, Inc. (REGN) Cantor Fitzgerald Virtual Global Healthcare Conference September 15, 2020 10:00 A.M. ET Company Participants Israel Lowy - SVP, Translational Sciences and Oncology Justin Holko - VP and Head, IR Conference Call Participants Alethia Young - Cantor Fitzgerald Presentation Alethia Young Hey everybody, its Alethia Young here...
SA Transcripts on Seeking Alpha | September 15, 2020
The biotechnology industry includes companies that develop drugs and diagnostic compounds for the treatment of diseases and medical conditions. These products must go through a rigorous, costly, and time-consuming testing process before potentially obtaining approval from the U.